https://charts.traderzeitung.de/phases/US48576U2050 string(1405) "{"isin":"US48576U2050","name":"Karyopharm Therapeutics Inc","stock_id_xnas":73260516,"stock_id_xnys":null,"generated_at":"2026-09-24 01:32:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.86,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.828,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":-1.7204},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.76,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-3.7199},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Karyopharm Therapeutics Aktie News & Nachrichten

[WKN: A40YLC | Symbol: KPTI]

Realtimekurs

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Karyopharm Therapeutics gefunden werden.

Karyopharm Therapeutics Nachrichtenticker öffnen

MT Newswires 31.07.2026 20:14 Uhr

Karyopharm Therapeutics Aktie News & Nachrichten

Artikel aus der Redaktion der Trader-Zeitung

Größte Verlierer am Mittag

Baird stuft Karyopharm Therapeutics von Outperform auf Neutral herab und passt das Kursziel von $15 auf $3 an

Karyopharm wird Daten aus der Phase-3-Studie von Selinexor plus Ruxolitinib bei Myelofibrose vorlegen